• Annexin-V Maps Cardiomyocyte Death After Cardiac I/R

  2026-08-21

  The reference study established labeled recombinant human annexin-V as an in situ method for detecting early cardiomyocyte death after myocardial ischemia and reperfusion. By resolving the timing of phosphatidylserine exposure in living mice, it provided a practical readout for evaluating interventions intended to limit ischemia/reperfusion-associated cell loss.

• Sulfachloropyridazine Research Workflows

  2026-08-20

  Sulfachloropyridazine connects DHPS-focused enzyme inhibition assays with antimicrobial susceptibility testing and microbiome-aware infection research. This workflow shows how to improve solubility control, interpret combination effects, and translate cecal microbiota findings into stronger experimental designs.

• Tankyrase Inhibition and the Hippo Cascade in HCC

  2026-08-20

  The reference study shows that XAV-939 and G007-LK suppress hepatocellular carcinoma cell growth while reducing YAP activity and increasing the YAP inhibitors AMOTL1 and AMOTL2. Its main contribution is to connect tankyrase inhibition with Hippo-pathway regulation, providing a mechanistic basis for combining tankyrase inhibitors with MEK or AKT pathway inhibitors.

• RepSox in hiPSC Platelet Differentiation Design

  2026-08-19

  RepSox is a potent ALK5 inhibitor for dissecting how TGF-β signaling influences hiPSC reprogramming and megakaryocyte maturation. This article connects a 2026 platelet-production study with a mechanistic, checkpoint-based assay strategy while separating validated findings from testable RepSox hypotheses.

• Carrier-Platin Triggers a Rapid ROS Storm in Cancer

  2026-08-19

  The reference study introduces carrier-platin, a platinum-based nanotherapeutic that confines ultrasmall platinum nanoparticles within a poly(amino acid) carrier to catalyze rapid intracellular ROS accumulation. Its reported cancer-killing activity occurs independently of DNA damage and differs from both apoptosis and ferroptosis, suggesting a distinct strategy for addressing drug-resistant tumors.

• Actinomycin D in LUAD: From Transcription to Translation

  2026-08-18

  Actinomycin D can serve as more than a cytotoxic reagent: it is a mechanistic stress test for connecting transcriptional control, mRNA persistence, and metastatic plasticity in lung adenocarcinoma. This article translates findings from the IGF2BP3/MCM5/Notch axis into a practical, evidence-aware workflow for mRNA stability, apoptosis induction, and translational model design.

• SAR131675: VEGFR-3 Inhibitor Workflow Guide

  2026-08-18

  SAR131675 enables selective interrogation of VEGFR-3-driven lymphatic endothelial survival, migration, and vascular remodeling. This workflow guide translates its nanomolar biochemical and cellular activity into practical assay design while separating validated anti-lymphangiogenic use-cases from exploratory kidney-disease applications.

• Clodronate Liposomes for In Vivo Macrophage Depletion

  2026-08-17

  Clodronate Liposomes provide phagocytosis-mediated delivery of liposome-encapsulated clodronate for experimental in vivo macrophage depletion. K2721 supports route- and tissue-specific macrophage perturbation, but depletion should not be interpreted as equivalent to CCL7 blockade or macrophage-specific genetic ablation.

• Actinomycin D Workflows for RNA Stability

  2026-08-17

  Actinomycin D converts transcriptional inhibition into a practical tool for mRNA decay, apoptosis induction, and transcriptional stress studies. This guide also shows how ActD can complement the circCHSY1–miR-24-3p–HO1 findings in myocardial ischaemia/reperfusion research without confusing a broad transcriptional perturbation with a gene-specific mechanism.

• Proteinase K: From DNA Prep to Assay Strategy

  2026-08-16

  Proteinase K is more than a routine digestion reagent: its substrate preference, inhibitor resilience, and compatibility with demanding buffers make it a strategic control point in genomic DNA workflows and protease assays. This article connects those properties to translational experimental design while defining what the evidence does—and does not—support.

• Hesperadin: Aurora B Kinase Inhibitor Workflows

  2026-08-15

  Hesperadin is an Aurora B kinase inhibitor for separating kinase-driven mitotic defects from broader cytotoxic effects. This practical guide covers assay setup, checkpoint-focused workflows, quantitative readouts, and troubleshooting for cell cycle and cancer research.

• Enhanced ECL Detection Kit for Gut–Tumor Biology

  2026-08-14

  The Enhanced ECL detection kit supports sensitive western blot analysis of the protein pathways connecting gut microbial metabolism with breast cancer progression. This article translates the Prevotella copri–IPyA–UHRF1–AMPK findings into a rigorous, decision-oriented protein immunodetection workflow.

• Myelin Swelling and Repair in CNS Demyelination

  2026-08-14

  Arafa and colleagues show that early CNS myelin damage is often marked by swelling rather than immediate sheath loss, and that some damaged sheaths can remodel or recover. Across zebrafish, rodent, and human tissue, the study identifies neuronal activity as a modifiable factor that can worsen or mitigate this early pathology.

• Q-VD-OPh: Separating Caspase Death from Mitophagy

  2026-08-13

  Q-VD-OPh gives translational researchers a powerful way to distinguish caspase-dependent cell death from mitochondrial quality-control responses. By pairing this pan-caspase inhibitor with Rab14–Parkin mitophagy assays, investigators can build more rigorous models of neurodegeneration, apoptosis, and post-cryopreservation recovery.

• Cy3 Goat Anti-Mouse IgG (H+L) Antibody Workflow

  2026-08-13

  Turn mouse primary-antibody binding into a bright, traceable Cy3 signal for immunofluorescence, western blotting, and flow cytometry. This workflow connects HMGB1 biomarker discovery with practical orthogonal validation while emphasizing controls, storage, and troubleshooting.

7910 records 3/528 page Previous Next 12345 下5页 Last page